Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism

 

Trial Design:

Prospective, randomised, open label, multicentre pilot study comparing dalteparin vs. rivoraxaban with a second placebo-controlled randomisation comparing the duration of anticoagulation therapy (6 months vs 12 months treatment) in Residual Vein Thrombosis [RVT] positive (+ve) patients.

Trial Status:

The select-d trial has closed to recruitment and is now in the follow-up phase.

The first randomisation closed on 22/12/2016 and the second randomisation closed on 28/02/2017.